

# Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid- $\beta$ peptide levels in vivo

Veronica Hirsch-Reinshagen,\* Jennifer Y. Chan,\* Anna Wilkinson,\* Tracie Tanaka,\* Jianjia Fan,\* George Ou,\* Luis F. Maia,<sup>†</sup> Roshni R. Singaraja,<sup>§</sup> Michael R. Hayden,<sup>§</sup> and Cheryl L. Wellington<sup>1,\*</sup>

Department of Pathology and Laboratory Medicine,\* University of British Columbia, Vancouver, Canada; Department of Neurology,<sup>†</sup> Hospital Geral de Santo Antonio, Porto, Portugal; and Centre for Molecular Medicine and Therapeutics,<sup>§</sup> University of British Columbia, Vancouver, Canada

**Abstract** ABCA1-deficient mice have low levels of poorly lipidated apolipoprotein E (apoE) and exhibit increased amyloid load. To test whether excess ABCA1 protects from amyloid deposition, we crossed APP/PS1 mice to ABCA1 bacterial artificial chromosome (BAC) transgenic mice. Compared with wild-type animals, the ABCA1 BAC led to a 50% increase in cortical ABCA1 protein and a 15% increase in apoE abundance, demonstrating that this BAC supports modest ABCA1 overexpression in brain. However, this was observed only in animals that do not deposit amyloid. Comparison of ABCA1/APP/PS1 mice with APP/PS1 controls revealed no differences in levels of brain ABCA1 protein, amyloid, A $\beta$ , or apoE, despite clear retention of ABCA1 overexpression in the livers of these animals. To further investigate ABCA1 expression in the amyloid-containing brain, we then compared ABCA1 mRNA and protein levels in young and aged cortex and cerebellum of APP/PS1 and ABCA1/APP/PS1 animals. Compared with APP/PS1 controls, aged ABCA1/APP/PS1 mice exhibited increased ABCA1 mRNA, but not protein, selectively in cortex. Additionally, ABCA1 mRNA levels were not increased before amyloid deposition but were induced only in the presence of extensive A $\beta$  and amyloid levels. These data suggest that an induction of ABCA1 expression may be associated with late-stage Alzheimer's neuropathology.—Hirsch-Reinshagen, V., J. Y. Chan, A. Wilkinson, T. Tanaka, J. Fan, G. Ou, L. F. Maia, R. R. Singaraja, M. R. Hayden, and C. L. Wellington. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or A $\beta$  peptide levels in vivo. *J. Lipid Res.* 2007. 48: 914–923.

**Supplementary key words** ATP binding cassette transporter A1 • apolipoprotein E • Alzheimer's disease • animal model

Apolipoprotein E (apoE) is a well-validated risk factor for late-onset Alzheimer's disease (AD) (1). In the central nervous system (CNS), apoE is secreted by astrocytes and microglia and serves as the major cholesterol carrier in

brain (2). ApoE also binds amyloid- $\beta$  peptide (A $\beta$ ) and is found in amyloid plaques (3, 4). ApoE-deficient mice deposit A $\beta$  but not amyloid, (5, 6), and the extent of amyloid deposition correlates with apoE gene dose (7). These findings suggest that factors that regulate apoE abundance may affect amyloidogenesis.

We and others have shown that ABCA1 modulates CNS apoE levels (8–10). ABCA1 effluxes cellular lipids onto lipid-poor apolipoprotein acceptors (11), and deficiency of ABCA1 results in nearly undetectable plasma HDL levels, impaired cholesterol efflux, and an increased risk of cardiovascular disease (12–14). In the brain, ABCA1 is expressed in neurons, astrocytes, and microglia and is induced by liver X receptor (LXR) and retinoic X receptor (RXR) agonists (15–18). ABCA1-deficient glia secrete less apoE than wild-type cells and are impaired in cholesterol efflux to apoE (8). These effects may underlie the drastic reduction in CNS apoE levels found in ABCA1-deficient mice and explain the poor lipidation of the remaining apoE particles (8–10).

Recently, we and others demonstrated that ABCA1 also modulates amyloid burden in vivo (19–21). Because apoE levels correlate with the extent of amyloid load, the reduced levels of apoE in ABCA1-deficient mice led to the prediction that fewer amyloid deposits would be observed in the absence of ABCA1. In contrast, ABCA1-deficient mice developed an equal or greater amyloid burden than wild-type mice in four independent models of AD (19–21), demonstrating that poorly lipidated apoE markedly promotes amyloidogenesis. These observations raise the converse possibility that selective overexpression of ABCA1 may enhance apoE lipidation and lead to reduced amyloid levels.

Abbreviations: A $\beta$ , amyloid- $\beta$  peptide; AD, Alzheimer's disease; apoE, apolipoprotein E; BAC, bacterial artificial chromosome; CNS, central nervous system; CSF, cerebrospinal fluid; LXR, liver X receptor; RXR, retinoic X receptor; Tg, transgenic; 24S-OH-Chol, 24S-hydroxycholesterol; 27-OH-Chol, 27-hydroxycholesterol.

<sup>1</sup>To whom correspondence should be addressed.

e-mail: cheryl@cmmt.ubc.ca

Manuscript received 28 June 2006 and in revised form 21 December 2006.  
Published, JLR Papers in Press, January 18, 2007.  
DOI 10.1194/jlr.M600543-JLR200

To test this possibility, we crossed the APP/PS1 mouse model of AD to *ABCA1* bacterial artificial chromosome (BAC) transgenic (Tg) mice, which express human *ABCA1* from endogenous regulatory signals (22). BAC Tg models are desirable for many *in vivo* investigations, as the transgene is expressed from physiologically relevant regulatory elements that conserve appropriate developmental and tissue-specific expression patterns (23). Accordingly, expression of human *ABCA1* from a BAC transgene has been shown to mirror that of endogenous murine *abca1* in multiple tissues, including brain (24), and protects from atherosclerosis in both whole animal and bone marrow transplant paradigms (25, 26).

Here, we report that although the *ABCA1* BAC leads to modestly increased *ABCA1* protein levels in brain, this is observed only in animals without amyloid deposits. In animals with advanced AD neuropathology, *ABCA1* protein levels are not increased by the presence of the *ABCA1* BAC, even though human and murine *ABCA1* mRNA levels are both increased. Accordingly, no changes in amyloid, apoE, or A $\beta$  levels are found between APP/PS1 mice in the absence or presence of human *ABCA1*. These observations suggest that the expression of *ABCA1* may be subject to transcriptional and posttranscriptional control in brain with advanced AD, which ultimately may attenuate *ABCA1* protein accumulation *in vivo*.

## MATERIALS AND METHODS

### Animals

*ABCA1* BAC Tg mice containing BAC RP11-32H03 have been described previously (27) and are maintained on a congenic C57Bl/6 genetic background. APP/PS1 (line 85) mice (Jackson Laboratories, Bar Harbor, ME) express a chimeric mouse/human APP650 cDNA containing the Swedish (KM670/671NL) mutation cointegrated with the human presenilin 1 (PS1) gene containing the  $\Delta$ E9 mutation (28) and are maintained on an F1 50% C3H, 50% C57Bl/6 genetic background. APP/PS1 mice were crossed to *ABCA1* BAC Tg animals, and double *ABCA1*/APP/PS1 Tg animals were compared with APP/PS1 littermate controls, all with a 75% C57Bl/6, 25% C3H genetic composition. Animals were maintained on a chow diet (PMI LabDiet 5010), and all animal procedures were in accordance with the Canadian Council of Animal Care and the University of British Columbia Committee on Animal Care.

### Protein extraction and Western blot

Murine tissue extractions were performed as described previously (19). Briefly, brain regions were homogenized in ice-cold PBS containing Complete protease inhibitor (Roche, Mississauga, Canada) in a Tissuemite homogenizer followed by centrifugation. The supernatant (soluble fraction) was then removed and used to evaluate soluble apoE. The pellets from the PBS solubilization step were resuspended in ice-cold lysis buffer containing 10% glycerol, 1% Triton X-100, and Complete protease inhibitor (Roche) in PBS and centrifuged to extract *ABCA1*. The pellet from this step (insoluble fraction) was finally solubilized in 5 M guanidine hydrochloride in 50 mM Tris-HCl, pH 8.0, to evaluate plaque-associated A $\beta$ . Brain tissues from all animals were extracted in an identical manner, and all fractions were immediately frozen at  $-80^{\circ}\text{C}$  until analysis. Liver tissues were homogenized directly into ice-cold lysis buffer containing 10% glycerol, 1% Triton X-100, and

Complete protease inhibitor (Roche) in PBS. Protein concentrations were determined by DC Protein Assay (Bio-Rad, Hercules, CA). For Western blots, tissue lysates were resolved by SDS-PAGE and immunodetected using a monoclonal anti-*ABCA1* antibody (AC10) (16) or an anti-GAPDH antibody (Chemicon, Temecula, CA) as a loading control. Blots were developed using enhanced chemiluminescence (Amersham, Piscataway, NJ) and quantified using NIH Image J software.

### ApoE ELISA

Murine apoE levels were determined by ELISA as described previously (9). Plates were coated with anti-apoE (WU E-4) (a kind gift from D. Holtzman, Washington University). Samples were diluted in 0.5% BSA and 0.025% Tween-20 in PBS. Standards were based on plasma from Swiss-Webster rats containing 61.7  $\mu\text{g}/\text{ml}$  apoE (9). After an overnight incubation at  $4^{\circ}\text{C}$ , plates were incubated with goat anti-apoE (EMD Biosciences, San Diego, CA) followed by biotinylated anti-goat antibody (Vector Laboratories, Burlington, CA). Plates were developed with poly-horseradish peroxidase streptavidin (Pierce, Rockford, IL) and ultra-slow 3,3',5,5'-tetramethylbenzidine (Sigma, St. Louis, MO), stopped with 1 N HCl, and read at 450 nm.

### Cerebrospinal fluid cholesterol measurements

Cerebrospinal fluid (CSF) was isolated as described previously (29). Total cholesterol measurements were performed using the fluorogenic Amplex Red Cholesterol Assay Kit (Molecular Probes, Burlington, CA).

### Neuropathological analyses

Thioflavine-S staining of amyloid plaques was performed and quantified as described (19). Human A $\beta$  levels were quantified by ELISA (Biosource, Camarillo, CA) and normalized to total protein.

### Quantitative RT-PCR

RNA was extracted using Trizol (Invitrogen, Burlington, CA) and treated with DNaseI. cDNA was generated using oligo-dT primers and Taqman reverse transcription reagents (Applied Biosystems, Foster City, CA). Quantitative real-time PCR primers were designed using PrimerExpress (Applied Biosystems) to span human- and murine-specific regions of *ABCA1* or regions identical in both species. Primer sequences and cycling conditions will be provided upon request. Real-time quantitative PCR was done with SYBR Green reagents (Applied Biosystems) on an ABI 7000 (Applied Biosystems). Each sample was assayed at least in duplicate, normalized to  $\beta$ -actin, and analyzed with 7000 system SDS software version 1.2 (Applied Biosystems) using the relative standard curve method.

### Statistical analysis

Data are shown as means  $\pm$  SEM and were analyzed by two-tailed unpaired Student's *t*-tests for comparisons between two groups or by one-way ANOVA with a Newman-Keul's posttest for comparisons among multiple groups. Welch's correction for unequal variances was applied when variances were significantly different between groups. Analyses were performed using GraphPad Prism (version 4.0; GraphPad, San Diego, CA).

## RESULTS

### *ABCA1* and apoE levels are increased in cortex of *ABCA1* BAC Tg mice

To test whether excess *ABCA1* can mitigate amyloid deposition, *ABCA1* BAC Tg mice were crossed to the APP/

PS1 model of AD, resulting in four groups of animals consisting of wild type, *ABCA1* BAC, APP/PS1, and *ABCA1*/APP/PS1 littermates that are optimally matched for their mixed (75% C57Bl/6, 25% C3H) genetic background. To first validate the *ABCA1* BAC Tg model for this study, we confirmed that the presence of the *ABCA1* BAC transgene resulted in increased *ABCA1* levels in adult brain (in animals of  $14.5 \pm 1.35$  months of age). Compared with wild-type animals, *ABCA1* protein levels were increased by  $\sim 50\%$  in *ABCA1* BAC Tg cortex and by  $\sim 100\%$  in liver (cortex,  $P = 0.0009$ ,  $n \geq 13$ ; liver,  $P = 0.0042$ ,  $n = 8$ ) (Fig. 1A). These values represent the sum of both human and murine *ABCA1* protein, as our *ABCA1* antibody does not distinguish between human and murine *ABCA1*. That human *ABCA1* expression was considerably more robust in the liver compared with the brain suggests that the endogenous regulatory sequences present on BAC RP11-23H03 are less efficiently recognized in brain, that BAC RP11-23H03 may be missing some elements required for robust expression in cells in the CNS, or that *ABCA1* may be expressed in a greater proportion of total cells in liver compared with brain.

We next determined whether increased brain *ABCA1* resulted in increased cortical and CSF apoE levels and CSF cholesterol (Fig. 1B). Consistent with the modest degree of *ABCA1* overexpression in the BAC Tg mice, PBS-soluble apoE levels were slightly, but significantly, increased by 15% in the cortex of *ABCA1* BAC Tg mice (mean apoE level = 185.1 ng/mg) compared with wild-type controls (mean apoE level = 160.9 ng/mg) ( $P = 0.036$ ,  $n \geq 12$ ). However, no significant changes were observed in either CSF apoE levels or CSF cholesterol in the presence of *ABCA1* overexpression. These data show that physiological overexpression of *ABCA1* protein in the BAC Tg model is sufficient to promote a subtle increase in apoE levels


in brain tissue but is unable to alter the levels or lipidation of circulating apoE in CSF, where particles are subject to remodeling.

### Amyloid burden and A $\beta$ and apoE levels are not changed by the presence of physiologically regulated human *ABCA1*


To determine whether excess *ABCA1* may inhibit amyloidogenesis in vivo, we then analyzed APP/PS1 mice with and without the *ABCA1* BAC at 14.5 months of age. No significant differences in amyloid burden, guanidine-extractable A $\beta$  levels, soluble apoE levels, or CSF cholesterol were observed between *ABCA1*/APP/PS1 Tg animals (APP/BAC+) relative to APP/PS1 littermate controls (APP/BAC-) (Fig. 2). These data show that physiologically regulated expression of human *ABCA1* from endogenous regulatory elements present on BAC RP11-32H03 does not significantly affect A $\beta$  or apoE metabolism in vivo in aged APP/PS1 mice.

### Human *ABCA1* is expressed in brain and liver of *ABCA1*/APP/PS1 mice but makes a significant contribution to total *ABCA1* protein levels only in liver

To determine whether the inability to detect a change in amyloid, A $\beta$ , apoE, or CSF cholesterol in the *ABCA1*/APP/PS1 mice could be attributed to an unexpected loss of *ABCA1* expression from the BAC, quantitative RT-PCR was used to quantify human, murine, and total *ABCA1* mRNA of *ABCA1*/APP/PS1 (APP/BAC+) mice compared with APP/PS1 littermates (APP/BAC-). Validation tests first confirmed that the human primers were unable to amplify murine *abca1* mRNA and that the murine primers did not amplify human *ABCA1* mRNA (data not shown). As expected, human *ABCA1* mRNA was present only in



**Fig. 1.** The *ABCA1* bacterial artificial chromosome (BAC) increases cortical and liver *ABCA1* and cortical apolipoprotein E (apoE) levels but does not affect cerebrospinal fluid (CSF) apoE or cholesterol. A: Total *ABCA1* protein in cortex and liver was measured by Western blot and quantitated by densitometry relative to GAPDH levels. Graphs are expressed as percentage of wild-type levels (wild-type animals were assigned a 100% level) and illustrate the pooled results of four independent measurements of 14 wild-type (WT) and 13 *ABCA1* BAC transgenic (Tg) (BAC+) cortical samples and at least two independent measurements of 8 wild-type and 8 *ABCA1* BAC Tg liver samples. Values shown are means  $\pm$  SEM. B: Left panel: PBS-soluble cortical apoE levels were measured by ELISA and normalized for total protein. The graph represents two independent experiments of 13 wild-type (WT) and 12 *ABCA1* BAC Tg (BAC+) samples measured in triplicate. Middle panel: CSF apoE levels were assessed by ELISA. The graph represents 14 wild-type (WT) and 9 *ABCA1* BAC Tg (BAC+) samples. Right panel: CSF total cholesterol was analyzed using the Amplex Red Cholesterol Assay Kit. The graph represents 13 wild-type (WT) and 9 *ABCA1* BAC Tg (BAC+) samples. Two-tailed Student's *t*-tests were used for statistical analyses.




**Fig. 2.** *ABCA1* BAC transgene expression has no significant effect on amyloid burden, A $\beta$  level, apoE abundance, or CSF cholesterol. **A:** Thioflavine-S staining of hemispherical sections from APP/PS1 hippocampi in the presence (APP/BAC+) and absence (APP/BAC-) of the *ABCA1* BAC transgene. Images show two individual mice per genotype and correspond to 2.5 $\times$  magnification of the hippocampus. Bar = 1,000  $\mu$ m. Amyloid load was quantitated for hippocampus and cingulate cortex in six APP/PS1 (APP/BAC-) and six *ABCA1*/APP/PS1 (APP/BAC+) animals. **B:** The graph is expressed as the percentage of Thioflavine-S-positive area over total area. **C, D:** Guanidine-extractable A $\beta$ 40 (**C**) and A $\beta$ 42 (**D**) were measured by ELISA and normalized for total protein. The graphs correspond to 10 APP/PS1 (APP/BAC-) and 10 *ABCA1*/APP/PS1 (APP/BAC+) animals. **E:** PBS-soluble cortical apoE levels were measured by ELISA and normalized for total protein. The graph represents two independent measurements (each performed in triplicate) of ten APP/PS1 (APP/BAC-) and ten *ABCA1*/APP/PS1 (APP/BAC+) animals. **F:** CSF cholesterol (Chol) levels were measured by Amplex Red assay in 20 APP/PS1 (APP/BAC-) and eight *ABCA1*/APP/PS1 (APP/BAC+) mice. In all graphs, sample size is indicated by the number within the bar. Two-tailed Student's *t*-tests were used for all statistical analyses. Values shown are means  $\pm$  SEM.

animals carrying the *ABCA1* BAC transgene (**Fig. 3A**), and murine *abca1* mRNA levels were similar in *ABCA1*/APP/PS1 (APP/BAC+) compared with APP/PS1 (APP/BAC-) mice, showing that the presence of the human *ABCA1* BAC transgene has no significant influence on murine *abca1* mRNA levels (**Fig. 3B**). Surprisingly, we observed no increase in total *ABCA1* mRNA ( $P > 0.05$ ,  $n \geq 6$ ) or protein ( $P > 0.05$ ,  $n \geq 10$ ) levels in cortical extracts prepared from APP/PS1 (APP/BAC-) and *ABCA1*/APP/PS1 (APP/BAC+) mice (**Fig. 3C-E**), suggesting that the human *ABCA1* BAC makes a negligible contribution to total *ABCA1* in the amyloid-containing brain.

*ABCA1* expression was also evaluated in the liver of these same mice. As expected, human *ABCA1* mRNA was detected only in animals carrying the *ABCA1* BAC transgene (**Fig. 4A**), and murine *abca1* mRNA levels were no different between groups (**Fig. 4B**). Unlike brain, however, total *ABCA1* mRNA and protein levels were increased by  $\sim$ 2-fold in *ABCA1*/APP/PS1 livers (APP/BAC+) compared with APP/PS1 controls (APP/BAC-) ( $P = 0.0345$ ,  $n \geq 5$  for mRNA,  $P = 0.0003$ ,  $n = 8$  for protein) (**Fig. 4D, E**). These results demonstrate that the human BAC remains functional after breeding to APP/PS1 mice but that its expression in brain may be altered in mice with amyloid deposits.

### ***ABCA1* mRNA but not protein levels are increased in the amyloid-containing brain**

To further explore these findings, we then compared *ABCA1* mRNA and protein levels in cortex and cerebellum in littermate mice of all four genotypes. Compared with wild-type mice, murine *abca1* mRNA levels were increased significantly in the cortex of APP/PS1 (APP/BAC-) ( $P < 0.05$ ,  $n = 8$ ) and *ABCA1*/APP/PS1 (APP/BAC+) ( $P < 0.05$ ,  $n = 6$ ) mice but were unchanged in cerebellum ( $P > 0.05$ ,  $n > 7$ ) (**Fig. 5A**). Similarly, human *ABCA1* mRNA levels were  $\sim$ 3-fold higher in cortex ( $P < 0.05$ ,  $n \geq 6$ ) but not in cerebellum ( $P > 0.05$ ,  $n \geq 7$ ) of *ABCA1*/APP/PS1 (APP/BAC+) compared with *ABCA1* BAC Tg (BAC+) mice (**Fig. 5B**). However, this increase in cortical *ABCA1* mRNA was not necessarily accompanied by a proportional increase of *ABCA1* protein. Compared with wild-type mice, animals with the *ABCA1* BAC alone or with the APP/PS1 transgenes alone each displayed a very modest but significant increase of total *ABCA1* protein in cortex ( $P < 0.01$ ,  $n \geq 10$ , each group compared with wild-type controls) (**Fig. 5C**). However, compared with APP/PS1 (APP/BAC-) mice, *ABCA1*/APP/PS1 (APP/BAC+) mice displayed no further increase in cortical *ABCA1* protein levels, despite having significantly increased murine and



**Fig. 3.** Human *ABCA1* expression in the cortex of APP/PS1 mice is insufficient to increase total *ABCA1* mRNA or protein levels. A–C: *ABCA1* mRNA levels were determined using quantitative RT-PCR using human-specific primers (A), murine-specific primers (B), or primers that do not distinguish between species (C). Graphs are expressed as fold difference of *ABCA1*/APP/PS1 (APP/BAC+) mice relative to APP/PS1 (APP/BAC–) controls, which were assigned an arbitrary value of 1. Numbers in each bar represent the number of independent animals that were analyzed, using at least duplicate measurements per animal. D, E: *ABCA1* protein levels were evaluated by Western blot and normalized to GAPDH as an internal loading control from  $\geq 10$  independent mice per genotype. Two-tailed Student's *t*-tests were used for all statistical analyses. Values shown are means  $\pm$  SEM.


human *ABCA1* mRNA levels relative to wild-type controls ( $P > 0.05$ ,  $n \geq 10$ ) (Fig. 5C). Cerebellar *ABCA1* protein levels showed no significant difference in *ABCA1* protein levels among groups ( $P > 0.05$ ,  $n \geq 8$ ) (Fig. 5C).

#### ***ABCA1* expression is induced only in mice with advanced disease**


The results described above showing that *ABCA1* mRNA levels are increased in aged APP/PS1 mice suggest that either *ABCA1* may be induced in response to A $\beta$  or amyloid deposition or the that the presence of the APP/PS1 transgenes may alter *ABCA1* expression even before amyloid neuropathology begins. To further determine the relationship between *ABCA1* expression and age, we examined *ABCA1* expression in cortex and cerebellum of young ( $2.7 \pm 0.24$  months) and old ( $12.7 \pm 0.71$  months) APP/PS1 mice. Because the human *ABCA1* BAC makes

little contribution to total *ABCA1* mRNA levels in brain, the animals used in this experiment were baseline APP/PS1 mice on an F1 50% C3H, 50% C57Bl/6 genetic background, which is slightly different from the animals analyzed above, on a 75% C57Bl/6, 25% C3H background.

As expected, murine *abca1* mRNA levels were not increased in 2.7 month old APP/PS1 cortex or cerebellum compared with wild-type controls ( $P > 0.05$ ,  $n \geq 4$  for each group) (Fig. 6A), demonstrating that *ABCA1* is not induced simply by expressing the APP and PS1 transgenes before the initiation of amyloid deposition. Also as expected, APP/PS1 mice showed no increase in cerebellar *abca1* mRNA expression even at 12.7 months of age (Fig. 6A, right panel). Unexpectedly, however, we did not observe a significant induction in cortical *abca1* mRNA levels in 12.7 month old APP/PS1 mice (Fig. 6A, left panel), in contrast with our observations in Fig. 5. No sig-



**Fig. 4.** Human *ABCA1* expression in the liver of APP/PS1 mice results in significant increases in total *ABCA1* mRNA and protein levels. A–C: *ABCA1* mRNA levels were determined using quantitative RT-PCR using human-specific primers (A), murine-specific primers (B), or primers that do not distinguish between species (C). Graphs are expressed as fold difference of *ABCA1*/APP/PS1 (APP/BAC+) mice relative to APP/PS1 (APP/BAC–) controls, which were assigned an arbitrary value of 1. Numbers in each bar represent the number of independent animals that were analyzed, using at least duplicate measurements per animal. D, E: *ABCA1* protein levels were evaluated by Western blot and normalized to GAPDH as an internal loading control from eight independent mice per genotype. Two-tailed Student's *t*-tests were used for all statistical analyses. Values shown are means  $\pm$  SEM.




**Fig. 5.** Regional specificity of ABCA1 induction. A, B: Murine (A) and human (B) *ABCA1* mRNA levels were determined in cortex (amyloid-rich) and cerebellum (amyloid-poor) of wild-type, *ABCA1* BAC, APP/PS1, and *ABCA1*/APP/PS1 mice using quantitative RT-PCR. Graphs are expressed as fold difference of all groups relative to wild-type controls, which were assigned an arbitrary value of 1. Data represent at least duplicate measurements for six to eight independent mice in each group. C: ABCA1 protein levels were evaluated by Western blot and normalized to GAPDH as an internal loading control from eight or more independent mice per genotype for each group, analyzed by one-way ANOVA. Data represent at least duplicate measurements per mouse. WT, wild type. Values shown are means  $\pm$  SEM.

nificant difference in ABCA1 protein abundance in cortex or cerebellum was observed in any group ( $P > 0.05$ ,  $n \geq 4$  mice/genotype) (Fig. 6B), consistent with the mRNA results.

These data show that ABCA1 mRNA clearly is not induced in mice before amyloid deposition. However, we were surprised that *abca1* mRNA levels were not increased in the cortex of APP/PS1 mice at 12.7 months of age, because we had previously observed significantly increased *abca1* mRNA levels in APP/PS1 (APP/BAC<sup>-</sup>) cortex at 14.5 months of age, when each cohort was compared with littermate controls appropriately matched for age as well as genetic background. Notably, the difference in ages of these two cohorts is statistically significant ( $P = 0.002$ ), and A $\beta$  levels increase steeply in the APP/PS1 model over the age ranges used in these experiments. Therefore, it is possible that ABCA1 is induced only upon reaching a

threshold level of A $\beta$  that occurs between 12 and 14 months of age. Alternatively, it is possible that genetic background also may affect the response of ABCA1 expression to amyloid pathology.

To determine whether A $\beta$  levels were indeed higher in the cohort with increased *abca1* mRNA levels, we directly compared guanidine-extractable A $\beta$  levels in cortex and cerebellum of 14.5 month old APP/PS1 (APP/BAC<sup>-</sup>) mice on the 25% C3H, 75% C57Bl/6 background (referred to as group A or APP/BAC<sup>-</sup>) with those in 12.7 month old APP/PS1 animals on the 50% C3H, 50% C57Bl/6 background (referred to as group B or APP/PS1) (Fig. 7). Neither group for this analysis contained the human *ABCA1* BAC transgene. Cerebellum was examined because it was negative for any changes in ABCA1 expression in all of the experiments described above, even




**Fig. 6.** ABCA1 mRNA is not increased in baseline APP/PS1 brains at  $\sim 3$  ( $2.7 \pm 0.243$ ) or  $\sim 13$  ( $12.7 \pm 0.713$ ) months of age. **A:** Murine *abca1* mRNA levels were determined in cortex and cerebellum using quantitative RT-PCR in 3- and 13-month old mice ( $n = 6-7$  mice/group). Graphs are expressed as fold difference of all groups relative to wild-type controls at 3 months of age. **B:** ABCA1 protein levels were evaluated by Western blot and normalized to GAPDH as an internal loading control from four to six mice per group, analyzed by Student's *t*-test. Data represent at least duplicate measurements per mouse, expressed relative to 3 month old wild-type (WT) mice that were arbitrarily assigned an ABCA1 protein level of 100%. Values shown are means  $\pm$  SEM.

though the presence of the PS1 $\Delta E9$  mutation in the APP/PS1 model of AD is associated with A $\beta$  and amyloid accumulation in the cerebellum. Thioflavine-S staining revealed that cerebellar amyloid deposits were present but not as extensive as in cortex (data not shown). A $\beta$ 40 levels were significantly higher in group A or APP/BAC $^{-}$  than in group B or APP/PS1 animals for both cortex ( $P = 0.038$ ,  $n \geq 6$ ) and cerebellum ( $P = 0.037$ ,  $n \geq 6$ ). Furthermore, cortex contained significantly more A $\beta$ 40 than cerebellum for both group A or APP/BAC $^{-}$  ( $P < 0.0001$ ,  $n \geq 6$ ) and group B or APP/PS1 ( $P = 0.003$ ,  $n \geq 6$ ) mice. Similarly, A $\beta$ 42 levels were significantly higher in group A or APP/BAC $^{-}$  than in group B or APP/PS1 animals in cortex ( $P = 0.039$ ,  $n \geq 6$ ) and cerebellum ( $P = 0.012$ ,  $n \geq 6$ ), and cortex contained significantly more A $\beta$ 42 than cerebellum for both group A (APP/BAC $^{-}$ ) ( $P < 0.0001$ ,  $n \geq 6$ ) and group B (APP/PS1) ( $P = 0.0004$ ,  $n \geq 6$ ) mice. These results demonstrate that even modest differences in age and/or genetic background significantly influence A $\beta$  burden in the APP/PS1 model. More importantly, because *abca1* mRNA levels were increased only in cortex of animals with the highest A $\beta$  levels (group A or APP/BAC $^{-}$  mice, 14.5 months of age, on a 25% C3H, 75% C57Bl/6 background), our results

suggest that ABCA1 mRNA may be induced only in response to very advanced amyloid deposition.

#### Soluble apoE levels are increased in mice with amyloid deposits

Because transcription of ABCA1 is clearly not impaired in the amyloid-containing brain, posttranscriptional regulatory mechanisms may impose an upper limit on ABCA1 protein levels achievable in aged APP/PS1 mice with extensive amyloid deposits. Wang et al. (30) previously reported that apolipoproteins, including apoA-I and apoE3, stabilize ABCA1 protein in primary macrophages, hepatocytes, and transfected HEK cells. To determine whether apoE levels may be limiting in the amyloid-containing brain, we measured PBS-soluble and guanidine-insoluble apoE levels in wild-type, ABCA1 BAC, APP/PS1, and ABCA1/APP/PS1 mice. Consistent with our previous observations (19), soluble apoE levels were increased  $\sim 2$ -fold in the amyloid-containing brain, and the presence of the ABCA1 BAC did not affect this increase ( $n = 10-13$ ,  $P < 0.001$ ) (Figs. 1 and 2). These data show that soluble apoE is present in excess in the amyloid-containing brain, suggesting that mechanisms other than apoE availability must contribute



**Fig. 7.** A $\beta$ 40 and A $\beta$ 42 levels are significantly influenced by age and/or genetic background. Guanidine-extractable A $\beta$ 40 (A) and A $\beta$ 42 (B) levels were determined by ELISA in cohorts of APP/PS1 mice on a 25% C3H, 75% C57Bl/6 background at 14.5 months of age (group A) compared with cohorts of APP/PS1 mice on a 50% C3H, 50% C57Bl/6 background at 12.7 months of age (group B). Each data point represents an individual mouse (group A cortex,  $n = 18$ ; group B cortex,  $n = 7$ ; group A cerebellum,  $n = 17$ ; group B cerebellum,  $n = 5$ ).

to the failure to observe increased ABCA1 protein levels in brain regions rich in amyloid deposits.

## DISCUSSION

ABCA1 is a critical regulator of apoE metabolism in the CNS (8, 9). We and others have demonstrated that deficiency of ABCA1 reduces the levels and lipidation of apoE, which results in enhanced amyloidogenesis in vivo (19–21). These findings raise the important question of whether overexpression of ABCA1 can increase apoE levels or lipidation and reduce amyloid burden. As a first step toward addressing this question, we crossed *ABCA1* BAC Tg mice to the APP/PS1 model of AD and analyzed the impact of human *ABCA1* on amyloid deposition, A $\beta$  levels, and apoE abundance. We specifically selected the *ABCA1* BAC Tg model because it expresses human *ABCA1* in a physiologically accurate manner (22, 24) that has been shown to be atheroprotective in vivo (25, 26). Furthermore, we confirmed that, in mice without amyloid deposits, *ABCA1* BAC Tg mice exhibit a subtle 50% increase in cortical ABCA1 protein and a very modest 15% increase in cortical apoE protein compared with wild-type controls. These data show that BAC RP11-32H03 supports a slight but significant overexpression of ABCA1 in brain.

However, the presence of the *ABCA1* BAC made no significant impact on amyloid burden, A $\beta$  levels, apoE abundance, or CSF cholesterol levels in aged APP/PS1 mice, raising the question of whether the BAC transgene remained functional in mice with amyloid deposits. Quantitative RT-PCR experiments demonstrated that human *ABCA1* mRNA was clearly present in *ABCA1*/APP/PS1 and not in APP/PS1 cortex, as expected. However, in amyloid-containing cortex, BAC RP11-32H03 did not make a significant contribution to the total ABCA1 mRNA pool; therefore, no increase in ABCA1 protein levels was detected. This is not attributable to a loss of global BAC transgene expression, because, in these same animals, human *ABCA1* constituted a significant proportion of total ABCA1 mRNA in liver and resulted in the expected increase in liver ABCA1 protein levels in *ABCA1*/APP/PS1 mice compared with APP/PS1 controls.

Further analysis revealed that ABCA1 expression appears to be responsive to local signals that may be generated in brain regions containing extensive amyloid deposits. Both human and murine ABCA1 mRNA levels were increased in cortex but not in cerebellum of aged *ABCA1*/APP/PS1 mice, demonstrating regional specificity in the ABCA1 transcriptional response. However, this local induction of ABCA1 mRNA does not necessarily lead to increased protein levels, as *ABCA1*/APP/PS1 mice, which have the highest levels of ABCA1 mRNA, did not display a proportional increase in cortical ABCA1 protein. In these cohorts, a very subtle increase in cortical ABCA1 protein was observed in the presence of the BAC transgene alone or in mice containing amyloid deposits, but these levels were not increased additively in mice with the BAC transgene as well as amyloid deposits. These observations

suggest that ABCA1 may also be subject to posttranscriptional regulatory mechanisms that may impose an upper limit on the degree to which physiologically regulated ABCA1 protein levels can be reached in brain regions that are prominently affected in AD.

Furthermore, induction of ABCA1 transcription was evident only in mice with the highest A $\beta$  and amyloid burdens. ABCA1 mRNA levels were not increased before amyloid deposition or in cohorts that contained abundant A $\beta$  and amyloid load at 12.7 months of age. In contrast, a separate cohort that was slightly older (14.5 months of age) and had a 2-fold increase in A $\beta$ 40 and A $\beta$ 42 levels did display a significant increase in ABCA1 transcription, although we cannot rule out the possibility that genetic background may also significantly influence ABCA1 expression. Even though we cannot distinguish between the effects of genetic composition and age in this analysis, our results clearly demonstrate that physiologically regulated ABCA1 mRNA is induced only in advanced disease.

The mechanisms underlying this complex regulation of ABCA1 expression in the amyloid-containing brain remain to be completely defined. Transcription of ABCA1 is regulated by LXR/RXR agonists in both peripheral and CNS cells (17, 18, 31). Two different subtypes of LXRs, LXR $\alpha$  and LXR $\beta$ , have been described (32). LXR $\alpha$  is expressed at low levels in the CNS (33), whereas LXR $\beta$  is expressed broadly and at high levels in rodent brain (34–37). Among LXR $\beta$  ligands, 24S-hydroxycholesterol (24S-OH-Chol) and 27-hydroxycholesterol (27-OH-Chol) have been implicated in AD (38–40), and both are reported to induce ABCA1 transcription (18, 41). 24S-OH-Chol is the major cholesterol metabolite in brain and the primary route of cholesterol egress from the CNS (42, 43). 24S-OH-Chol is synthesized in the brain by cholesterol 24-hydroxylase, which in humans is expressed nearly exclusively in neurons (40, 42, 44, 45). In contrast, mice and rats generate only 50% and 70% 24S-OH-Chol in the brain, respectively (46, 47). 24S-OH-Chol levels in plasma and CSF are reported to be increased in subjects with mild to moderate AD (48–50), reflecting increased brain cholesterol turnover during the early stages of AD, when neurodegeneration is beginning. In severe to end-stage AD, however, extensive neuronal loss results in an eventual decline in 24S-OH-Chol levels in brain, CSF, and plasma (38, 40, 51). In contrast, 27-OH-Chol is produced in most peripheral cells (52), and the level of 27-OH-Chol in brain tissue is normally so low that it is useful as a marker of increased blood-brain barrier permeability and sterol influx into the CNS. Notably, the levels of 27-OH-Chol have been reported to be increased in postmortem human AD tissue and in the APP23 model of AD at ages concomitant with amyloid deposition (40), consistent with reports of blood-brain barrier leakiness as an early feature of AD pathogenesis (53). However, no differences were observed in brain 24S-OH-Chol levels in aging APP23 mice (54), suggesting either that changes during AD pathogenesis may be too subtle to detect in mice that have a broader cholesterol 24-hydroxylase distribution than humans or that the lack of extensive neurodegeneration in many models of

AD may result in little net change in 24-OH-Chol. Additional studies will be required to elucidate whether these or other oxysterols may be involved in the transcriptional response of ABCA1 to amyloid deposits.

ABCA1 expression is also regulated at the posttranscriptional level. In cholesterol-loaded macrophages, ABCA1 is degraded by the proteasomal system in a process that requires a functional Niemann-Pick type C gene (55). This pathway may be relevant during neurodegeneration, when increased free cholesterol is released from dying neurons and scavenged by microglia. In addition, both unsaturated and saturated fatty acids regulate ABCA1 protein stability in vitro (56, 57). ABCA1 contains a PEST sequence from amino acids 1,283–1,306 that modulates protein degradation by calpain (30). Residues tyrosine 1,286 and tyrosine 1,305 within the PEST sequence are normally constitutively phosphorylated, which results in a rapid turnover of ABCA1 in the absence of apolipoproteins. These residues become dephosphorylated in the presence of apoA-I or apoE, which stabilize ABCA1 by inhibiting calpain-mediated degradation (30, 58). We considered the possibility that limited amounts of soluble apoE, the major apolipoprotein in brain, may contribute to the lack of ABCA1 protein accumulation when ABCA1 mRNA levels are high. However, here we show that soluble apoE levels are in fact increased 2-fold in cortex with extensive amyloid deposits. This observation suggests that mechanisms other than apoE availability must contribute to the failure to accumulate high levels of ABCA1 protein in the amyloid-containing cortex.

Our findings pose a potential challenge to the consideration of using selective ABCA1 overexpression as a therapeutic means to increase apoE levels or lipidation in brains expected to develop AD neuropathology. Although we show that excess physiologically regulated ABCA1 can result in increased brain apoE levels, this was only observed in animals without amyloid deposits. It remains to be determined whether driving selective ABCA1 expression to much higher levels in the brain, for example using exogenous nonphysiological promoters, can override the regulatory mechanisms that appear to attenuate the expression of ABCA1 protein in the amyloid-containing brain and whether this will lead to increases in apoE levels and lipidation that will be sustained in the presence of AD neuropathology. Our study clearly demonstrates that physiologically regulated excess ABCA1 is unable to mitigate AD neuropathology in mice and suggests for the first time that ABCA1 may also be subject to transcriptional and posttranscriptional regulation during the pathogenesis of AD. **FIG**

The authors thank Leo Basso, David Holtzman, and Suzanne Wahrle for invaluable comments and for sharing the apoE ELISA and CSF methodology with our group. The authors are grateful to Kate Naus and Sean McIsaac for superb technical assistance. V.H.R. is supported by the Canadian Institutes of Health Research (CIHR). M.R.H. is supported by the CIHR and the British Columbia and Yukon Heart and Stroke Foundation and holds a Canada Research Chair in Human Genetics. C.L.W. is supported by the CIHR and the Alzheimer's Society of Canada.

## REFERENCES

1. Tanzi, R. E., and L. Bertram. 2001. New frontiers in Alzheimer's disease genetics. *Neuron*. **32**: 181–184.
2. Ladu, M. J., C. Reardon, L. Van Eldik, A. M. Fagan, G. Bu, D. Holtzman, and G. S. Getz. 2000. Lipoproteins in the central nervous system. *Ann. N. Y. Acad. Sci.* **903**: 167–175.
3. Atwood, C. S., R. N. Martins, M. A. Smith, and G. Perry. 2002. Senile plaque composition and posttranslational modification of amyloid- $\beta$  peptide and associated proteins. *Peptides*. **23**: 1343–1350.
4. Burns, M. P., W. J. Noble, V. Olm, K. Gaynor, E. Casey, J. LaFrancois, L. Wang, and K. Duff. 2003. Co-localization of cholesterol, apolipoprotein E and fibrillar A $\beta$  in amyloid plaques. *Brain Res. Mol. Brain Res.* **110**: 119–125.
5. Bales, K. R., T. Verina, R. Dodel, Y. Du, L. Alsteil, M. Bender, P. Hyslop, E. M. Johnstone, S. P. Little, D. J. Cummins, et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid  $\beta$ -peptide deposition. *Nat. Genet.* **17**: 263–264.
6. Fagan, A. M., M. Watson, M. Parsadanian, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2002. Human and murine apoE markedly alters A $\beta$  metabolism before and after plaque formation in a mouse model of Alzheimer's disease. *Neurobiol. Dis.* **9**: 305–318.
7. Bales, K. R., T. Verina, D. J. Cummins, Y. Du, R. C. Dodel, J. Saura, C. E. Fishman, C. A. DeLong, P. Piccardo, V. Petegnief, et al. 1999. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA*. **96**: 15233–15238.
8. Hirsch-Reinshagen, V., S. Zhou, B. L. Burgess, L. Bernier, S. A. McIsaac, J. Y. Chan, G. H. Tansley, J. S. Cohn, M. R. Hayden, and C. L. Wellington. 2004. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. *J. Biol. Chem.* **279**: 41197–41207.
9. Wahrle, S. E., H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J. D. Fryer, T. Kowalewski, and D. M. Holtzman. 2004. ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. *J. Biol. Chem.* **279**: 40987–40993.
10. Burns, M. P., L. Vardanian, A. Pajoohesh-Gangi, L. Wang, M. Cooper, D. C. Harris, K. Duff, and G. W. Rebeck. 2006. The effects of ABCA1 on cholesterol efflux and A $\beta$  levels in vitro and in vivo. *J. Neurochem.* **98**: 792–800.
11. Hayden, M. R., S. M. Clee, A. Brooks-Wilson, J. Genest, Jr., A. Attie, and J. P. Kastelein. 2000. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. *Curr. Opin. Lipidol.* **11**: 117–122.
12. Brooks-Wilson, A., M. Marcil, S. M. Clee, L. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. F. Molhuizen, et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. *Nat. Genet.* **22**: 336–345.
13. Bodzioch, M., E. Ors , J. Klucken, T. Langmann, A. B ttcher, W. Diederich, W. Drobnik, S. Barlage, C. B chler, M. Porsch- zc r mez, et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat. Genet.* **22**: 347–351.
14. Rust, S., M. Rosier, H. Funke, Z. Amoura, J.-C. Piette, J.-F. Deluize, H. B. Brewer, Jr., N. Duverger, P. Den fle, and G. Assmann. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat. Genet.* **22**: 352–355.
15. Lawn, R. M., D. P. Wade, T. L. Couse, and J. N. Wilcox. 2001. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. *Arterioscler. Thromb. Vasc. Biol.* **21**: 378–385.
16. Wellington, C. L., E. K. Walker, A. Suarez, A. Kwok, N. Bissada, R. Singaraja, Y.-Z. Yang, L. H. Zhang, E. James, J. E. Wilson, et al. 2002. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. *Lab. Invest.* **82**: 273–283.
17. Koldamova, R. P., I. M. Lefterov, M. D. Ikonovic, J. Skoko, P. I. Lefterov, B. A. Isanski, S. T. DeKosky, and J. S. Lazo. 2003. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid  $\beta$  secretion. *J. Biol. Chem.* **278**: 13244–13256.
18. Abildayeva, K., P. J. Jansen, V. Hirsch-Reinshagen, V. W. Bloks, A. H. F. Bakker, F. C. S. Ramaekers, J. de Vante, A. K. Groen, C. L. Wellington, F. Kuipers, et al. 2006. 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. *J. Biol. Chem.* **281**: 12799–12808.
19. Hirsch-Reinshagen, V., L. F. Maia, B. L. Burgess, J. F. Blain, K. E. Naus, S. A. McIsaac, P. F. Parkinson, J. Y. Chan, G. H. Tansley, M. R. Hayden, et al. 2005. The absence of ABCA1 decreases soluble apoE

- levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. *J. Biol. Chem.* **280**: 43243–43256.
20. Koldamova, R., M. Staufenbiel, and I. Lefterov. 2005. Lack of ABCA1 considerably decreased brain apoE level and increases amyloid deposition in APP23 mice. *J. Biol. Chem.* **280**: 43224–43235.
21. Wahrle, S., H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2005. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. *J. Biol. Chem.* **280**: 43236–43242.
22. Singaraja, R. R., V. Bocher, E. R. James, S. M. Clee, L.-H. Zhang, B. R. Leavitt, B. Tan, A. Brooks-Wilson, A. Kwok, N. Bissada, et al. 2001. Human ABCA1 BAC transgenic mice show increased HDL-C and apoA1-dependent efflux stimulated by an internal promoter containing LXREs in intron 1. *J. Biol. Chem.* **276**: 33969–33979.
23. Giraldo, P., and L. Montoliu. 2003. Size matters: use of YACs, BACs and PACs in transgenic animals. *Transgenic Res.* **10**: 83–103.
24. Singaraja, R. R., E. R. James, J. Crim, H. Visscher, A. Chatterjee, and M. R. Hayden. 2005. Alternate transcripts expressed in response to diet reflect tissue-specific regulation of ABCA1. *J. Lipid Res.* **46**: 2061–2071.
25. Singaraja, R., C. Fievet, G. Castro, E. R. Jammers, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J.-C. Fruchart, B. M. McManus, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. *J. Clin. Invest.* **110**: 35–42.
26. Van Eck, M., R. R. Singaraja, D. Ye, R. B. Hildebrand, E. R. James, M. R. Hayden, and T. J. Van Berkel. 2006. Macrophage ATP-binding cassette transporter 1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. *Arterioscler. Thromb. Vasc. Biol.* **26**: 929–934.
27. Coutinho, J. M., R. R. Singaraja, M. Kang, D. J. Arenillas, L. N. Bertram, N. Bissada, B. Staels, J. C. Fruchart, C. Fievet, A. M. Joseph-George, et al. 2005. Complete functional rescue of the ABCA1<sup>-/-</sup> mouse by human BAC transgenesis. *J. Lipid Res.* **46**: 1113–1123.
28. Borchelt, D. R., T. Ratovitski, J. van Lare, M. K. Lee, V. Gonzales, N. A. Jenkins, N. G. Copeland, D. L. Price, and S. S. Sisodia. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin-1 and amyloid precursor protein. *Neuron.* **19**: 939–945.
29. DeMattos, R. B., K. R. Bales, M. Parsadanian, M. A. O'Dell, E. M. Foss, S. M. Paul, and D. M. Holtzman. 2002. Plaque-associated disruption of CSF and plasma amyloid- $\beta$  (A $\beta$ ) equilibrium in a mouse model of Alzheimer's disease. *J. Neurochem.* **81**: 229–236.
30. Wang, N., W. Chen, P. Linsel-Nitschke, L. O. Martinez, B. Agerholm-Larsen, D. L. Silver, and A. R. Tall. 2003. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. *J. Clin. Invest.* **111**: 99–107.
31. Oram, J. F., and J. W. Heinecke. 2005. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. *Physiol. Rev.* **85**: 1343–1372.
32. Peet, D. J., B. A. Janowski, and D. J. Mangelsdorf. 1998. The LXRs: a new class of oxysterol receptors. *Curr. Opin. Genet. Dev.* **8**: 571–575.
33. Apfel, R., D. Benbrook, E. Lernhardt, M. A. Ortiz, G. Salbert, and M. Pfahl. 1994. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. *Mol. Cell. Biol.* **14**: 7025–7035.
34. Song, C., J. M. Kokontis, R. A. Hiipakka, and S. Liao. 1994. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. *Proc. Natl. Acad. Sci. USA.* **91**: 10809–10813.
35. Teboul, M., E. Enmark, Q. Li, A. C. Wikstrom, M. Pelto-Huikko, and J. A. Gustafsson. 1995. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. *Proc. Natl. Acad. Sci. USA.* **92**: 2096–2100.
36. Seol, W., H. S. Choi, and D. D. Moore. 1995. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. *Mol. Endocrinol.* **9**: 72–85.
37. Kainu, T., J. Kononen, E. Enmark, J. A. Gustafsson, and M. Pelto-Huikko. 1996. Localization and ontogeny of the orphan receptor OR-1 in the rat brain. *J. Mol. Neurosci.* **7**: 29–39.
38. Bretillon, L., A. Siden, L. O. Wahlund, D. Lutjohann, L. Minthon, M. Crisby, J. Hillert, C. G. Groth, U. Diczfalusy, and I. Bjorkhem. 2000. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. *Neurosci. Lett.* **293**: 87–90.
39. Lutjohann, D., K. von Bergmann, H. Bardenheuer, T. Hartmann, K. von Bergmann, K. Beyreuther, and J. Schröder. 2002. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. *Neurosci. Lett.* **324**: 83–85.
40. Heverin, M., N. Bogdanovic, D. Lutjohann, T. Bayer, I. Pikuleva, L. Bretillon, U. Diczfalusy, B. Winblad, and I. Bjorkhem. 2004. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. *J. Lipid Res.* **45**: 186–193.
41. Fu, X., J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow, and E. G. Lund. 2001. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. *J. Biol. Chem.* **276**: 38378–38387.
42. Lund, E. G., J. M. Guileyardo, and D. W. Russell. 1999. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. *Proc. Natl. Acad. Sci. USA.* **96**: 7238–7243.
43. Lutjohann, D., and K. von Bergmann. 2003. 24S-Hydroxycholesterol: a marker of brain cholesterol metabolism. *Pharmacopsychiatry.* **36 (Suppl. 2)**: 102–106.
44. Bjorkhem, I., D. Lutjohann, U. Diczfalusy, L. Stahle, G. Ahlberg, and J. Wahren. 1998. Cholesterol homeostasis in the human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. *J. Lipid Res.* **39**: 1594–1600.
45. Meaney, S., M. Hassan, A. Sakinis, D. Lutjohann, K. von Bergmann, U. Wennmalm, U. Diczfalusy, and I. Bjorkhem. 2001. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. *J. Lipid Res.* **42**: 70–78.
46. Meaney, S., D. Lutjohann, U. Diczfalusy, and I. Bjorkhem. 2000. Formation of oxysterols from different pools of cholesterol as studies by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. *Biochim. Biophys. Acta.* **1486**: 293–298.
47. Lund, E. G., C. Xie, T. Kotti, S. D. Turley, J. M. Dietschy, and D. W. Russell. 2003. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. *J. Biol. Chem.* **278**: 22980–22988.
48. Lutjohann, D., A. Papassotiropoulos, I. Bjorkhem, S. Locatelli, M. Bagli, R. D. Oehring, U. Schlegel, F. Jessen, M. L. Rao, K. von Bergmann, et al. 2000. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. *J. Lipid Res.* **41**: 195–198.
49. Papassotiropoulos, A., D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, R. Buschfort, U. Ptok, I. Bjorkhem, K. von Bergmann, and R. Heun. 2002. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. *J. Psychiatr. Res.* **36**: 27–32.
50. Schonknecht, P., D. Lutjohann, J. Pantel, H. Bardenheuer, T. Hartmann, K. von Bergmann, K. Beyreuther, and J. Schroder. 2002. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. *Neurosci. Lett.* **324**: 83–85.
51. Kolsch, H., R. Heun, A. Kerksiek, K. von Bergmann, W. Maier, and D. Lutjohann. 2004. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. *Neurosci. Lett.* **368**: 303–308.
52. Lund, E., O. Andersson, J. Zhang, A. Babiker, G. Ahlberg, U. Diczfalusy, K. Einarsson, J. Sjoval, and I. Bjorkhem. 1996. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. *Arterioscler. Thromb. Vasc. Biol.* **16**: 793–799.
53. Ujji, M., D. L. Dickstein, D. A. Carlow, and W. A. Jefferies. 2003. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. *Microcirculation.* **10**: 463–470.
54. Lutjohann, D., A. Brzezinka, E. Barth, D. Abramowski, M. Staufenbiel, K. von Bergmann, K. Beyreuther, G. Multhaup, and T. A. Bayer. 2002. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. *J. Lipid Res.* **43**: 1078–1085.
55. Feng, B., and I. Tabas. 2002. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. *J. Biol. Chem.* **277**: 43271–43280.
56. Wang, Y., and J. F. Oram. 2002. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. *J. Biol. Chem.* **277**: 5692–5697.
57. Wang, Y., B. Kurdi-Haidar, and J. F. Oram. 2004. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. *J. Lipid Res.* **45**: 972–980.
58. Martinez, L. O., B. Agerholm-Larsen, N. Wang, W. Chen, and A. R. Tall. 2003. Phosphorylation of a Pest sequence in ABCA1 promotes calpain degradation and is reversed by apoA-I. *J. Biol. Chem.* **278**: 37368–37374.